All In Biotech

Drug Trial Radar · NCT07059403

A Study of SN2001 Dose, Safety & Immunogenicity in Healthy Adults

A Phase I, Randomized, Double Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability and Immunogenicity of SN2001 in Healthy Adult Subjects

Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

Aug 19, 2025

Primary completion

Apr 2027

Study completion Apr 2027

Sponsor

Lead sponsor
Chimivac INCIndustry
Sponsor type
Industry
First posted
Jul 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled, multiple-ascending-dose study of SN2001 in healthy adult subjects. The study is designed to evaluate the safety, tolerability and immunogenicity of SN2001.

Conditions

  • Chronic Hepatitis B Infection

Interventions

  • SN2001Biological

    100 µg, for subcutaneous (SC) injection

  • SN2001Biological

    200 µg, for subcutaneous (SC) injection

  • SN2001Biological

    300 µg, for subcutaneous (SC) injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events (AEs)Time frame: from the time of the first study injection through 48 Weeks after the final study injection
  2. Number of subjects with clinically significant abnormalities in vital signs graded by 2007 FDA Guidance.Time frame: from the time of the first study injection through 48 Weeks after the final study injection
  3. Number of subjects with clinically significant abnormalities in physical examination graded by 2007 FDA Guidance.Time frame: from the time of the first study injection through 48 Weeks after the final study injection
  4. Number of subjects with clinically significant abnormalities in 12-lead electrocardiogram (ECG) graded by 2007 FDA Guidance.Time frame: from the time of the first study injection through 48 Weeks after the final study injection
  5. Number of subjects with clinically significant abnormalities in laboratory parameters graded by 2007 FDA Guidance.Time frame: from the time of the first study injection through 48 Weeks after the final study injection

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Q-Pharm Pty Ltd.

    Herston, Queensland, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.